First Patient Enrolled in Japan Prostate Cancer Trial
Global Phase 3 data for 177Lu‑PSMA‑I&T have met the primary endpoint with statistically significant, clinically meaningful benefit in metastatic...
BioStem Aligns with FDA’s Bayesian Clinical Trial Approach
In a randomized study of diabetic foot ulcers, BioStem’s BioRetain-processed allografts were reported to be nearly twice as likely...
Neomorph Doses First Patient in NEO-811 Cancer Trial
Neomorph has opened dosing in its first-in-human Phase 1/2 study of NEO-811, an oral, cereblon-dependent molecular glue degrader being...
Theriva to Present VCN-01 Retinoblastoma Trial Data at APAO
Theriva Biologics will present safety and clinical outcomes from an investigator-sponsored Phase 1 study of intravitreal VCN-01 (zabilugene almadenorepvec)...
BioCardia to Present Late-Breaking CardiAMP HF Trial Data
No efficacy or safety numbers were disclosed. BioCardia’s CardiAMP autologous cell therapy will be featured as a Late Breaking...
Radical Acceleration: Transforming Clinical Research Timelines Through AI and Systems Integration
At the 2026 SCOPE Summit, industry veterans and technology leaders convened to address a staggering economic reality: the cost...
Merck Outlines Strategic Shift Toward Clinical Trial Simplification and AI Integration
At the 2026 SCOPE Summit, Dr. Eliav Barr, Head of Global Clinical Development and Chief Medical Officer at Merck...
Arcutis’ Zoryve Cream: A Promising Trial for Infant Eczema
Fifty-eight percent of infants treated with roflumilast cream 0.05% achieved EASI-75 at Week 4 in an open-label Phase 2...
Successful Milestone for Actinogen’s Alzheimer’s Trial
An independent Data Monitoring Committee reviewed unblinded interim data from approximately 37% of Actinogen’s pivotal XanaMIA Alzheimer’s disease trial...
Successful 52-Week Phase 3 Acne Trial Data for ASC40
Denifanstat’s long-term safety profile in acne was clean in Ascletis’ open-label Phase 3 extension: among 240 patients treated once...